Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19 Vaccines: Placebo Crossover May Depend Upon Number Of Doses, Allocation Strategy

Executive Summary

Although US FDA wants sponsors to maintain blinded Phase III follow-up as long as possible after emergency use authorization or licensure, vaccine researcher Larry Corey says it will become ‘untenable’ to keep individuals in placebo arm once they qualify for vaccine access under the allocation framework.

You may also be interested in...



NIH Considering Trial of COVID-19 Vaccines and Asymptomatic Transmission

US FDA’s Peter Marks says transmission prevention is one of three key missing data points he’d like from Pfizer and BioNTech’s newly authorized vaccine. Another concern is how the vaccine will work is the virus “drifts.”

Placebo-Control Strategy After EUA Remains Big Question For Pfizer/BioNTech COVID-19 Vaccine

Pfizer intends to notify placebo patients that an EUA has been issued and offer the vaccine to keep them in the study, but FDA appears to want to maintain placebo control for as long as possible.

CBER Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., Marks Says

Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel